CareDx, Inc.: stock overview

CDNANASDAQHealthcare · Services-Medical Laboratories

Price

$77.88

November 13, 2026Market cap $4.0B

What Ploutos Investor adds for CareDx

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 14 fiscal years, from 2012
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

In short

CareDx had revenue of $497M over the last 12 months and net income of $129M, a net margin of 25.9%. Revenue grew by 14.6% a year on average over the last 5 years. At $77.88 the shares trade at a P/E of 31.0. It holds more cash than debt, by $250M. It pays no dividend.

From its SEC filings (latest fiscal year to December 31, 2025) and the price of November 13, 2026.

Its SEC filings
Market cap
$4.0B
51.22M shares
P/E
31.0
Revenue, 12 months
$497M
+14.6% a year over 5 years
Net margin
25.9%
2025: -5.6%, above 35% of its industry

Worth knowing

What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.

3 fiscal years in figures

Each fiscal year's figures as the company filed them, and the share price at its end.

2023–2025 fiscal years

+16.4% a year over 2 years

  • 202510-K
    Revenue$380M
  • 202410-K
    Revenue$334M
  • 202310-K
    Revenue$280M

Fiscal years in figures

CDNA's revenue, profit, cash flow and dividend with each year-end price, from 2012 to 2022, 11 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

Key figures

The company's current figures in five groups. Each term is explained behind its ⓘ.

Valuation

Market cap 3-year median: $965M
$4.0B
Enterprise value 
$3.7B
P/E 
31.0
EV / EBIT 
32.1
EV / Revenue 
7.5
P/B 3-year median: 3.1
8.5
FCF yield 
–
Earnings yield 3-year median: -2.1%
3.2%

Profitability

Operating margin 
23.4%
Net margin 3-year median: -5.6%
25.9%
ROIC 
25.3%
ROIC, 5-year average 
-16.0%
ROE 
35.3%

Growth

Revenue, yearly change 
+13.8%
EPS, yearly change 
-143.0%
FCF, yearly change 
–
Revenue, average a year 
+14.6%

The yearly change compares FY2025 with FY2024.

Balance sheet

Cash 
$250M
Total debt 
$29M
Of which operating leases 
$29M
Net cash 
$250M
Net debt / EBITDA 
-1.9x
Interest cover 
–
Current ratio 
2.31

Balance sheet of September 30, 2026.

Returns to shareholders

Dividend yield 
0.00%
Buybacks 
2.20%
Total returned 
2.20%
Shares, yearly change 
-7.6%
Valuation against its own pastEach fiscal year's P/E, P/FCF and P/B beside today's, and the DCF calculator for the company.Valuation

Against its industry

Where its margins and returns stood in fiscal 2025 among the SEC filers of its industry (SIC code 80).

Operating margin

-8.1%

Above 27% of the 62 companies in its industry, and 22% of all.

Net margin

-5.6%

Above 35% of the 68 companies in its industry, and 23% of all.

ROE

-7.0%

Above 28% of the 58 companies in its industry, and 21% of all.

ROA

-5.2%

Above 27% of the 69 companies in its industry, and 20% of all.

Revenue growth

13.8%

Above 54% of the 68 companies in its industry, and 71% of all.

From the yearly figures every company files with the SEC, for those with revenue of at least $25 million. The industry is the first two digits of the SIC code.

The company at the SEC

How it is registered and when its fiscal year ends.

Name at the SEC
CareDx, Inc.
Exchange
NASDAQ
Industry (SIC)
8071 · Services-Medical Laboratories
Fiscal year ends
December 31
Latest annual report
December 31, 2025
Reporting currency
USD
Shares
51.22M

Other companies: Healthcare

The largest companies of the same sector, each with its own page.

The Healthcare sectorAll companies

The full analysis

What do CareDx's filings show?

These are CareDx's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about CDNA

Didn't find what you were looking for?

Ask us
What is CDNA's market cap?

CareDx, Inc.'s market cap is $4.0B, at a price of $77.88 on November 13, 2026 and 51.22M shares.

What is CDNA's P/E?

CDNA's P/E is 31.0, on earnings per share of $2.39 over the last 12 months.

How much revenue does CDNA have?

CareDx had revenue of $497M over the last 12 months. Over the last 5 years it changed by +14.6% a year on average.

Does CDNA pay a dividend?

No. CareDx paid no regular dividend over the last 12 months.

Where do the figures come from?

From CareDx, Inc.'s SEC filings (10-K and 10-Q) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.